Extension and refinement of the predictive value of different classes of markers in ADNI: Four-year follow-up data

Alzheimer's and Dementia

Volumn 10, Issue 6, 2014, Pages 704-712

  Gomar, Jesus J ^a,b   Conejero Goldberg, Concepcion ^a   Davies, Peter ^a,c   Goldberg, Terry E ^a,c  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b Fundacion Para la Investigacion y Docencia Maria Angustias Gimenez   (Spain)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

Author keywords

Alzheimer's disease; Cognition; CSF; Mild cognitive impairment; MRI; PET FDG

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE; TAU PROTEIN; AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ASSESSMENT; CLOCK DRAWING SCREENING TEST; COGNITION ASSESSMENT; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE COURSE; DISEASE MARKER; EPISODIC MEMORY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; MILD COGNITIVE IMPAIRMENT; MORPHOMETRICS; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; TEMPORAL CORTEX; CEREBROSPINAL FLUID; COMPLICATION; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MEMORY, EPISODIC; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PSYCHIATRIC STATUS RATING SCALES; TAU PROTEINS;

EID: 84927177447     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.11.009     Document Type: Article

References (35)

1. C.P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, and M. Ganguli Global prevalence of dementia: a Delphi consensus study Lancet 366 2005 2112 2117
2. J.J. Gomar, M.T. Bobes-Bascaran, C. Conejero-Goldberg, P. Davies, and T.E. Goldberg Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's Disease Neuroimaging Initiative Arch Gen Psychiatry 68 2011 961 969
3. M Ewers, C Walsh, JQ Trojanowski, LM Shaw, RC Petersen, and C.R. Jack Jr. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance Neurobiol Aging 33 2012 1203 1214
4. D. Heister, J.B. Brewer, S. Magda, K. Blennow, and L.K. McEvoy Predicting MCI outcome with clinically available MRI and CSF biomarkers Neurology 77 2011 1619 1628
5. BM Jedynak, A Lang, B Liu, E Katz, Y Zhang, and BT Wyman A computational neurodegenerative disease progression score: method and results with the Alzheimer's Disease Neuroimaging Initiative cohort Neuroimage 63 2012 1478 1486
6. P.J. Snyder The retooling of old cognitive tests as an interim step on the path to validating a next generation of neuropsychological paradigms and assays Alzheimers Dement 9 2013 S1 S3
7. C.G. Begley, and L.M. Ellis Drug development: raise standards for preclinical cancer research Nature 483 2012 531 533
8. C.G. Begley Six red flags for suspect work Nature 497 2013 433 434
9. R.S. Desikan, L.K. McEvoy, W.K. Thompson, D. Holland, J.B. Brewer, and P.S. Aisen Amyloid-beta-associated clinical decline occurs only in the presence of elevated P-tau Arch Neurol 69 2012 709 713
10. K. Chen, N. Ayutyanont, J.B. Langbaum, A.S. Fleisher, C. Reschke, and W. Lee Characterizing Alzheimer's disease using a hypometabolic convergence index Neuroimage 56 2011 52 60
11. M.F. Folstein, S.E. Folstein, and P.R. McHugh "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189 198
12. J.C. Morris The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 43 1993 2412 2414
13. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow, and L. Minthon Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study Lancet Neurol 5 2006 228 234
14. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
15. R.S. Desikan, L.K. McEvoy, W.K. Thompson, D. Holland, J.C. Roddey, and K. Blennow Amyloid-beta associated volume loss occurs only in the presence of phospho-tau Ann Neurol 70 2011 657 661
16. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
17. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
18. R.C. Mohs, D. Knopman, R.C Petersen, S.H. Ferris, C. Ernesto, and M. Grundman Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 1997 S13 S21
19. H. Goodglass, and E. Kaplan The assessment of aphasia and related disorders 1983 Lea & Febiger Philadelphia, PA
20. D. Wechsler Wechsler Memory Scale-Revised 1987 The Psychological Corporation San Antonio, TX
21. A. Rey L'examen clinique en psychologie 1964 Presses Universitaires de France Paris, France
22. JC Morris, A Heyman, RC Mohs, JP Hughes, G van Belle, and G Fillenbaum The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease Neurology 39 1989 1159 1165
23. R.M. Reitan, and D. Wolfson The Halstead-Reitan Neuropsychological Test Battery 1985 Neuropsychology Press Tucson, AZ
24. D. Wechsler Wechsler Adult Intelligence Scale-Revised 1981 The Psychological Corporation San Antonio, TX
25. R.I. Pfeffer, T.T. Kurosaki, C.H. Harrah Jr., J.M. Chance, and S. Filos Measurement of functional activities in older adults in the community J Gerontol 37 1982 323 329
26. D.P. Devanand, X. Liu, M.H. Tabert, G. Pradhaban, K. Cuasay, and K. Bell Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease Biol Psychiatry 64 2008 871 879
27. C. Eckerstrom, E. Olsson, M. Bjerke, H. Malmgren, A. Edman, and A. Wallin A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia J Alzheimers Dis 36 2013 421 431
28. P.J. Nestor, P. Scheltens, and J.R. Hodges Advances in the early detection of Alzheimer's disease Nat Med 10 2004 S34 S41
29. M.C. Tierney, C. Yao, A. Kiss, and I. McDowell Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years Neurology 64 2005 1853 1859
30. I. Driscoll, S.M. Resnick, J.C. Troncoso, Y. An, R. O'Brien, and A.B. Zonderman Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly Ann Neurol 60 2006 688 695
31. D.G. Darby, R.H. Pietrzak, J. Fredrickson, M. Woodward, L. Moore, and A. Fredrickson Intraindividual cognitive decline using a brief computerized cognitive screening test Alzheimers Dement 8 2012 95 104
32. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
33. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
34. B. Schmand, P. Eikelenboom, and W.A. van Gool Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment J Alzheimers Dis 29 2012 641 648
35. R.C. Petersen Alzheimer's disease: progress in prediction Lancet Neurol 9 2010 4 5